Nuveen LLC Buys Shares of 161,149 Xencor, Inc. $XNCR

Key Points

• Nuveen LLC has acquired a new stake in Xencor, Inc., purchasing 161,149 shares valued at approximately $1.7 million, representing 0.23% ownership as of the end of the last quarter.
• Investment analysts have mixed opinions on Xencor's prospects, with an average price target of $23.71 and seven analysts rating it as a "Buy" while one analyst issued a "Sell" rating.
• Xencor's latest earnings report showed a significant revenue increase of 82.4% year-over-year, with reported revenue of $43.61 million, beating estimates by $21.02 million.

Nuveen LLC purchased a new stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 161,149 shares of the biopharmaceutical company's stock, valued at approximately $1,715,000. Nuveen LLC owned 0.23% of Xencor at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. New York State Teachers Retirement System boosted its holdings in Xencor by 2.1% in the 1st quarter. New York State Teachers Retirement System now owns 59,326 shares of the biopharmaceutical company's stock valued at $631,000 after purchasing an additional 1,200 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Xencor during the 4th quarter worth $34,000. Exchange Traded Concepts LLC lifted its holdings in shares of Xencor by 23.9% during the 1st quarter. Exchange Traded Concepts LLC now owns 9,814 shares of the biopharmaceutical company's stock worth $104,000 after acquiring an additional 1,896 shares during the last quarter. Comerica Bank lifted its holdings in shares of Xencor by 12.1% during the 4th quarter. Comerica Bank now owns 20,527 shares of the biopharmaceutical company's stock worth $472,000 after acquiring an additional 2,219 shares during the last quarter. Finally, CWM LLC lifted its holdings in shares of Xencor by 195.5% during the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 2,231 shares during the last quarter.

Insiders Place Their Bets

In other Xencor news, Director Kurt A. Gustafson sold 2,993 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the transaction, the director owned 20,183 shares of the company's stock, valued at approximately $186,087.26. This trade represents a 12.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard J. Ranieri sold 2,993 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the transaction, the director directly owned 19,183 shares of the company's stock, valued at $176,867.26. This represents a 13.50% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,194 shares of company stock worth $103,209. Company insiders own 5.23% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on XNCR. Barclays dropped their price objective on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a report on Thursday, May 8th. Wedbush dropped their price objective on shares of Xencor from $31.00 to $26.00 and set an "outperform" rating for the company in a report on Thursday, August 7th. Wells Fargo & Company dropped their price objective on shares of Xencor from $33.00 to $27.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Finally, Royal Bank Of Canada dropped their price objective on shares of Xencor from $32.00 to $15.00 and set an "outperform" rating for the company in a report on Thursday, August 21st. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, Xencor currently has a consensus rating of "Moderate Buy" and a consensus price target of $23.71.

Xencor Trading Up 1.0%

Xencor stock traded up $0.08 during trading hours on Monday, hitting $8.13. 769,384 shares of the stock traded hands, compared to its average volume of 743,533. Xencor, Inc. has a one year low of $6.92 and a one year high of $27.24. The firm's 50-day moving average price is $8.28 and its two-hundred day moving average price is $9.77. The company has a market cap of $579.83 million, a PE ratio of -3.39 and a beta of 0.82.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.78) by $0.37. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The firm had revenue of $43.61 million for the quarter, compared to the consensus estimate of $22.59 million. During the same quarter in the prior year, the business earned ($1.07) EPS. The business's revenue for the quarter was up 82.4% on a year-over-year basis. On average, sell-side analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.